The Protocol Review and Monitoring System (PRMS) oversees and ensures the prioritization, feasibility, scientific merit and progress of all clinical studies at the Cancer Therapy and Research Center (CTRC). The PRMS consists of three components that work in collaboration with one another to ensure that the right trials for the right population with the right resources open and accrue. This occurs via each of the committee's prioritization, feasibility, scientific review and progress in the selection and activation of all trials at CTRC. The PRMS evaluation process occurs prior to submission to submission to the UTHSCSA Institutional Review Board (IRB) and is required for IRB approval. The PRMS process is complementary to the IRB review and does not overlap or duplicate the responsibilities of the IRB. The IRB will not approve a protocol without the PRC's approval. Protocols are initially discussed in Clinical Disease Site Teams (CDST) teams where they receive priority scoring. Operations and Logistics Committee (O&L) where they are reviewed for feasibility, and then the Protocol Review Committee (PRC) where they receive data safety and monitoring, scientific and biostatistical reviews. After a study has opened to accrual, the PRC provides ongoing review to ensure adequate accrual and scientific progress. The PRC has the authority to close studies that have not progressed toward their intended scientific objectives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-20
Application #
8758431
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M3))
Project Start
1997-08-01
Project End
2019-07-31
Budget Start
2014-09-16
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$77,682
Indirect Cost
$39,732
Name
University of Texas Health Science Center
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Azpurua, Jorge; Mahoney, Rebekah E; Eaton, Benjamin A (2018) Transcriptomics of aged Drosophila motor neurons reveals a matrix metalloproteinase that impairs motor function. Aging Cell 17:
Bandyopadhyay, Abhik; Favours, Edward; Phelps, Doris A et al. (2018) Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatr Blood Cancer 65:
Gorthi, Aparna; Romero, July Carolina; Loranc, Eva et al. (2018) EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature 555:387-391
Yu, Xiaojie; Zhang, Yiqiang; Cavazos, David et al. (2018) miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death Dis 9:193
Chen, Chen; Zhao, Shujie; Karnad, Anand et al. (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11:64
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152

Showing the most recent 10 out of 989 publications